A monoclonal antibody (mAb) is a laboratory-produced molecule that is engineered to serve as a substitute for natural antibodies in the immune system. Unlike polyclonal antibodies, which are derived from multiple B‑cell lineages and recognize multiple epitopes on an antigen, monoclonal antibodies are homogeneous, recognizing a single, specific epitope.
Structure and Production
Monoclonal antibodies are immunoglobulin proteins consisting of two identical heavy chains and two identical light chains linked by disulfide bonds, forming a Y‑shaped structure. They are typically generated using hybridoma technology, a method developed in 1975 by Georges Köhler and César Milstein. In this process, a specific B‑cell producing the desired antibody is fused with an immortal myeloma cell line, creating a hybridoma that can proliferate indefinitely while secreting large quantities of a single type of antibody. Subsequent engineering techniques, including recombinant DNA technology and phage display, enable the production of fully human or humanized monoclonal antibodies to reduce immunogenicity.
Classification
Monoclonal antibodies are categorized based on their source and structure:
- Murine – fully mouse-derived antibodies (e.g., mouse IgG).
- Chimeric – variable regions from mouse antibodies fused to human constant regions (≈ 65 % human).
- Humanized – only the complementarity‑determining regions (CDRs) are of mouse origin, the remainder is human (≈ 90–95 % human).
- Fully human – derived from human gene sequences, often produced using transgenic mice or phage display libraries.
Therapeutic Applications
Monoclonal antibodies constitute a major class of biopharmaceuticals. As of 2023, over 100 mAbs have received regulatory approval worldwide for indications including:
- Oncology – targeting cell‑surface antigens (e.g., rituximab against CD20, trastuzumab against HER2/neu).
- Autoimmune diseases – modulating cytokine pathways (e.g., adalimumab against tumor necrosis factor‑α, natalizumab against α4‑integrin).
- Infectious diseases – neutralizing pathogens (e.g., palivizumab against respiratory syncytial virus, recent SARS‑CoV‑2–specific antibodies).
- Transplant medicine – preventing graft rejection (e.g., basiliximab against IL‑2 receptor).
Monoclonal antibodies can exert therapeutic effects through mechanisms such as direct antagonism of receptor signaling, induction of antibody‑dependent cellular cytotoxicity (ADCC), complement‑dependent cytotoxicity (CDC), or delivery of cytotoxic payloads in antibody‑drug conjugates (ADCs).
Diagnostic and Research Uses
In research laboratories and clinical diagnostics, monoclonal antibodies serve as highly specific reagents for protein detection, purification, and quantification. Techniques that employ mAbs include flow cytometry, immunohistochemistry, western blotting, enzyme‑linked immunosorbent assay (ELISA), and point‑of‑care rapid tests.
Safety and Limitations
While monoclonal antibodies are generally well tolerated, adverse effects can include infusion‑related reactions, immunogenicity leading to anti‑drug antibody formation, and off‑target effects. The high specificity that underlies therapeutic efficacy may also limit efficacy against heterogeneous tumor cell populations or rapidly mutating pathogens.
Regulatory and Manufacturing Considerations
Manufacture of monoclonal antibodies requires adherence to Good Manufacturing Practice (GMP) standards, as they are biologics with complex three‑dimensional structures sensitive to production conditions. Biosimilarity assessments are performed for subsequent versions of approved mAbs to ensure comparable safety and efficacy.
Historical Context
The concept of a monoclonal antibody emerged from the discovery of B‑cell clones capable of producing identical antibodies. The Nobel Prize in Physiology or Medicine (1984) was awarded to Köhler, Milstein, and Niels Jerne for their contributions to the development of hybridoma technology. Since then, advances in genetic engineering and cell‑culture techniques have expanded the scope and accessibility of monoclonal antibody therapeutics.